Illumina (ILMN) Tops Q3 EPS by 10c, Guides Below

November 1, 2016 4:10 PM EDT
Get Alerts ILMN Hot Sheet
Trade ILMN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Illumina (NASDAQ: ILMN) reported Q3 EPS of $0.97, $0.10 better than the analyst estimate of $0.87. Revenue for the quarter came in at $607 million versus the consensus estimate of $614.31 million.


Illumina sees FY2016 EPS of $3.27-$3.32, versus the consensus of $3.38.

"While sequencing sample volume growth remains robust, our lowered revenue outlook reflects our updated expectations for HiSeq 2500, HiSeq 4000 and HiSeq X instrument purchases, as well as HiSeq 2500 reagent sales,” stated Francis deSouza, President and CEO. “Over the last few weeks it has become clear that certain academic funding practices were modified in the third quarter, limiting our customers’ ability to make HiSeq X capital commitments. Further, HiSeq 2500 and 4000 demand has been impacted by a migration to NextSeq, for enhanced workflow flexibility and HiSeq X, given its beneficial pricing for whole genome sequencing.”

For earnings history and earnings-related data on Illumina (ILMN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Management Comments

Related Entities


Add Your Comment